Jump to main content
Jump to site search

Issue 1, 2003
Previous Article Next Article

Transformations of cyclic nonaketides by Aspergillus terreus mutants blocked for lovastatin biosynthesis at the lovA and lovC genes

Author affiliations

Abstract

Two mutants of Aspergillus terreus with either the lovC or lovA genes disrupted were examined for their ability to transform nonaketides into lovastatin 1, a cholesterol-lowering drug. The lovC disruptant was able to efficiently convert dihydromonacolin L 5 or monacolin J 9 into 1, and could also transform desmethylmonacolin J 15 into compactin 3. In contrast, the lovA mutant has an unexpectedly active β-oxidation system and gives only small amounts of 1 upon addition of the immediate precursor 9, with most of the added nonaketide being degraded to heptaketide 22. Similarly, the lovA mutant does not accumulate the polyketide synthase product 5 and rapidly degrades any 5 added as a precursor via two cycles of β-oxidation and hydroxylation at C-6 to give 20. The possible involvement of epoxides 21a and 21b in the biosynthesis of 1 was also examined, but their instability in fermentation media and fungal cells will require purified enzymes to establish their role.

Graphical abstract: Transformations of cyclic nonaketides by Aspergillus terreus mutants blocked for lovastatin biosynthesis at the lovA and lovC genes

Back to tab navigation

Supplementary files

Article information


Submitted
07 Aug 2002
Accepted
18 Sep 2002
First published
21 Nov 2002

Org. Biomol. Chem., 2003,1, 50-59
Article type
Paper

Transformations of cyclic nonaketides by Aspergillus terreus mutants blocked for lovastatin biosynthesis at the lovA and lovC genes

J. L. Sorensen, K. Auclair, J. Kennedy, C. Richard Hutchinson and J. C. Vederas, Org. Biomol. Chem., 2003, 1, 50
DOI: 10.1039/B207721C

Social activity

Search articles by author

Spotlight

Advertisements